The largest domestic drug maker Ranbaxy Laboratories is planning to introduce two of Daiichi Sankyos discovered products in
Olmesartan medoxomil is already available in more than 50 countries worldwide. Additionally, the two companies plan to promote Prasugrel, an anti-platelet, co-developed by Daiichi Sankyo and Eli Lilly, in the Latin American market. Prasugrel will be co-promoted by Lilly's affiliate in
With an estimated population of 107 million people,
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1645.25 |
| Dr. Reddys Lab | 1215.30 |
| Cipla | 1213.45 |
| Zydus Lifesciences | 912.50 |
| Lupin | 2330.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: